ABUS vs ALL
Arbutus Biopharma Corp (ABUS) versus The Allstate Corporation (ALL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
The Allstate Corporation (ALL) is a insurance - property & casualty company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
ALL does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. ALL currently screens at market cap $56.89B and trailing P/E 4.9.
Not investment advice. Open the ABUS and ALL stock pages for the full models.
Not investment advice.